Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medro vs MyStart Health

Medro
Graded #252

Lower grade

vs+3.499999999999993
MyStart Health
Graded #168

Higher grade

The verdict

MyStart Health takes it — 67.1/100 to 63.6/100.

MyStart Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MyStart Health offers all-inclusive compounded semaglutide and tirzepatide at $299/month with a price-lock guarantee, same-day physician consultations, and 24/7 care team access.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedro +2
50
48
Dose & formulationMyStart Health +6
77
83
Clinical oversightMyStart Health +13
71
84
Labs & monitoringMyStart Health +14
52
66
FulfillmentMedro +14
92
78
Contract termsMedro +2
33
31
Medro · left barMyStart Health · right bar

The numbers

MetricMedroMyStart Health
WeighScore63.6/10067.1/100
GradeCC
Scorecard rank#252#168
Semaglutide$199/mo (compounded)$299/mo (all doses, compounded)
Tirzepatide$299/mo (compounded)$299/mo (all doses, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
Medro

Graded #252 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
MyStart Health

Graded #168 · C

Strengths

  • Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
  • Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
  • 24/7 care team access with unlimited clinician messaging included
  • LegitScript certified
  • Clear Section 503A compounding disclosure on every landing page

Where it loses points

  • Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
  • Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
  • Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
  • Very new company (incorporated May 2024) with a limited track record
  • Pharmacy partners not named, so 503A compliance can't be independently verified

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard